Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance-Reference-Cited by-同舟云学术

Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance

Published:2023-08-17 Issue:8 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Tait Jessica R.¹,Harper Marina²^ORCID,Cortés-Lara Sara³⁴,Rogers Kate E.¹,López-Causapé Carla³⁴,Smallman Thomas R.²,Lang Yinzhi⁵,Lee Wee Leng¹,Zhou Jieqiang⁵,Bulitta Jürgen B.⁵^ORCID,Nation Roger L.¹,Boyce John D.²^ORCID,Oliver Antonio³⁴^ORCID,Landersdorfer Cornelia B.¹^ORCID

Affiliation:

1. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia

2. Biomedicine Discovery Institute, Department of Microbiology, Monash University, Melbourne, Victoria, Australia

3. Servicio de Microbiología, Hospital Universitario Son Espases-IdISBa, Palma de Mallorca, Spain

4. CIBER Enfermedades Infecciosas (CIBERINFEC), Madrid, Spain

5. Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA

Abstract

Pseudomonas aeruginosa remains a challenge in chronic respiratory infections in cystic fibrosis (CF). Ceftolozane-tazobactam has not yet been evaluated against multidrug-resistant hypermutable P. aeruginosa isolates in the hollow-fiber infection model (HFIM). Isolates CW41, CW35, and CW44 (ceftolozane-tazobactam MICs of 4, 4, and 2 mg/L, respectively) from adults with CF were exposed to simulated representative epithelial lining fluid pharmacokinetics of ceftolozane-tazobactam in the HFIM.

Funder

DHAC | National Health and Medical Research Council

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00414-23

Reference73 articles.

1. Cystic Fibrosis Foundation. 2022. Cystic fibrosis foundation patient registry 2021 annual data report. https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf. Accessed 26 March 2023.

2. Predictors of mortality in adults with cystic fibrosis

3. Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis

4. High Frequency of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Lung Infection

5. Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lytic transglycosylase Slt of Pseudomonas aeruginosa as a periplasmic hub protein;Protein Science;2024-06-12

2. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing;International Journal of Antimicrobial Agents;2024-06

3. Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa;Antimicrobial Agents and Chemotherapy;2024-04-03